Literature DB >> 28927058

Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients.

Hiromichi Nakayama1, Kenoki Ohuchida1,2, Masaki Yoshida1, Tetsuyuki Miyazaki3, Shin Takesue1, Toshiya Abe1, Sho Endo1, Kazuhiro Koikawa1, Takashi Okumura1, Taiki Moriyama1, Kohei Nakata1, Yoshihiro Miyasaka1, Kengo Shirahane1, Tatsuya Manabe1, Takao Ohtsuka1, Hiroki Toma1, Yohei Tominaga1, Eishi Nagai1, Kazuhiro Mizumoto1, Yoshinao Oda3, Masafumi Nakamura1.   

Abstract

Pancreatic cancer is characterized by increased hyperplasia of fibrotic tissue, termed desmoplasia, and lymph node metastasis is an independent prognostic factor in this disease. However, there are no reports focused on desmoplasia in pancreatic cancer lymph node metastases. The present study evaluated a range of factors and investigated their association with poor prognosis in pancreatic cancer cases with lymph node metastasis, including the degree of desmoplasia in lesions. To identify the poor prognostic factors associated with lymph node metastasis, the present study retrospectively reviewed the clinical data of 65 patients with lymph node metastases that underwent surgical pancreatic cancer resection between 2007 and 2012 at a single institution. The investigation focused on the degree of fibrosis in metastatic lesions in 216 lymph nodes, and investigated associations with prognosis or clinicopathological findings. The ratios of the fibrotic area in metastatic lymph node lesions were evaluated and classified into three categories, high (≥70%), moderate (10-70%) and low (<10%). Desmoplasia was not observed in cancer-free lymph nodes. The size of metastatic lymph node lesions was additionally measured, and a significant association between metastatic lesion size and the degree of desmoplasia was observed (P<0.001). The degree of desmoplasia was additionally associated with local extranodal invasion. In the analysis of 65 pancreatic cancer patients with metastatic lymph nodes, the presence of multiple metastatic lymph nodes with moderate or high desmoplasia was significantly associated with poor survival (high, P=0.0048; moderate/high, P=0.0075). Of several clinicopathological factors, the presence of multiple metastatic lymph nodes with high or moderate desmoplasia was associated with overall survival in univariate (P=0.0098) and multivariate (P=0.0466) analyses. The degree of desmoplasia in metastatic lymph nodes is associated with lesion size, and the presence of multiple metastatic lymph nodes with desmoplasia is an independent poor prognostic factor, suggesting that the desmoplasia may have an important role in the malignant progression of lymph node metastases.

Entities:  

Keywords:  desmoplasia; locally extranodal invasion; lymph node metastasis; pancreatic cancer; prognostic factor

Year:  2017        PMID: 28927058      PMCID: PMC5588067          DOI: 10.3892/ol.2017.6549

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

Review 1.  Tumor-stroma interactions in pancreatic ductal adenocarcinoma.

Authors:  Daruka Mahadevan; Daniel D Von Hoff
Journal:  Mol Cancer Ther       Date:  2007-04-03       Impact factor: 6.261

2.  Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial.

Authors:  Yuji Nimura; Masato Nagino; Sonshin Takao; Tadahiro Takada; Koji Miyazaki; Yoshifumi Kawarada; Shuichi Miyagawa; Akihiro Yamaguchi; Shuichi Ishiyama; Yutaka Takeda; Kourou Sakoda; Taira Kinoshita; Kenzo Yasui; Hiroshi Shimada; Hiroyuki Katoh
Journal:  J Hepatobiliary Pancreat Sci       Date:  2012-05       Impact factor: 7.027

Review 3.  Pancreatic cancer.

Authors:  Audrey Vincent; Joseph Herman; Rich Schulick; Ralph H Hruban; Michael Goggins
Journal:  Lancet       Date:  2011-05-26       Impact factor: 79.321

4.  Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia.

Authors:  Soo Youn Cho; Tae Hyun Lee; Yun Hyi Ku; Hong Il Kim; Guk Haeng Lee; Min Joo Kim
Journal:  Surgery       Date:  2014-10-14       Impact factor: 3.982

5.  alpha-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma.

Authors:  Hayato Fujita; Kenoki Ohuchida; Kazuhiro Mizumoto; Kohei Nakata; Jun Yu; Tadashi Kayashima; Lin Cui; Tatsuya Manabe; Takao Ohtsuka; Masao Tanaka
Journal:  Pancreas       Date:  2010-05-07       Impact factor: 3.327

6.  Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.

Authors:  Clifford J Whatcott; Caroline H Diep; Ping Jiang; Aprill Watanabe; Janine LoBello; Chao Sima; Galen Hostetter; H Michael Shepard; Daniel D Von Hoff; Haiyong Han
Journal:  Clin Cancer Res       Date:  2015-02-18       Impact factor: 12.531

Review 7.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 8.  Extranodal extension in N1-adenocarcinoma of the pancreas and papilla of Vater: a systematic review and meta-analysis of its prognostic significance.

Authors:  Claudio Luchini; Nicola Veronese; Antonio Pea; Giuseppe Sergi; Enzo Manzato; Alessia Nottegar; Marco Solmi; Paola Capelli; Aldo Scarpa
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-02       Impact factor: 2.566

9.  α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.

Authors:  M Sinn; C Denkert; J K Striefler; U Pelzer; J M Stieler; M Bahra; P Lohneis; B Dörken; H Oettle; H Riess; B V Sinn
Journal:  Br J Cancer       Date:  2014-10-14       Impact factor: 7.640

10.  The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.

Authors:  Lai Mun Wang; Michael A Silva; Zenobia D'Costa; Robin Bockelmann; Zahir Soonawalla; Stanley Liu; Eric O'Neill; Somnath Mukherjee; W Gillies McKenna; Ruth Muschel; Emmanouil Fokas
Journal:  Oncotarget       Date:  2016-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.